Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Net Income (2018 - 2025)

Serina Therapeutics (SER) has disclosed Net Income for 8 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 15.07% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Dec 2025, down 37.9% year-over-year, with the annual reading at -$19.2 million for FY2025, 71.46% down from the prior year.
  • Net Income hit -$6.4 million in Q4 2025 for Serina Therapeutics, roughly flat from -$6.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $65000.0 in Q4 2023 to a low of -$6.4 million in Q4 2025.
  • Historically, Net Income has averaged -$3.1 million across 5 years, with a median of -$2.7 million in 2022.
  • Biggest five-year swings in Net Income: tumbled 37300.0% in 2022 and later skyrocketed 102.36% in 2023.
  • Year by year, Net Income stood at -$7000.0 in 2021, then crashed by 39328.57% to -$2.8 million in 2022, then surged by 102.36% to $65000.0 in 2023, then plummeted by 8663.08% to -$5.6 million in 2024, then fell by 15.07% to -$6.4 million in 2025.
  • Business Quant data shows Net Income for SER at -$6.4 million in Q4 2025, -$6.4 million in Q3 2025, and -$5.6 million in Q2 2025.